Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

July 15, 2015

Primary Completion Date

May 15, 2021

Study Completion Date

May 15, 2021

Conditions
Neuroendocrine Cancer
Interventions
DRUG

Carfilzomib

Trial Locations (10)

29303

Spartanburg Regional Medical Center/Gibbs Cancer Center, Spartanburg

32804

Florida Hospital Cancer Institute, Orlando

33705

Florida Cancer Specialists - North, St. Petersburg

33916

Florida Cancer Specialists, Fort Myers

37203

Tennessee Oncology PLLC, Nashville

45219

Oncology Hematology Care, INC., Cincinnati

60426

Ingalls Cancer Research Center, Harvey

64132

Research Medical Center, Kansas City

76104

Center for Cancer and Blood Disorders, Fort Worth

80218

Rocky Mountain Cancer Center, Denver

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER